Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Integrated BioPharma Inc. (INBP) had Revenue of $54.35M for the most recently reported fiscal year, ending 2025-06-30.

Quarterly Annual

Figures for fiscal year ending 2025-06-30

Income Statement Financials
Revenue	$54.35M
Net Income	$0.81M
Cost of Goods Sold	$48.79M
Gross Profit	$5.56M
Operating Expenses	$52.33M
Operating Income	$2.02M
Non-Operating Income/Expense	$0.04M
Pre-Tax Income	$2.06M
Normalized Pre-Tax Income	$2.06M
Income after Taxes	$0.81M
Income from Continuous Operations	$0.81M
Consolidated Net Income/Loss	$0.81M
Normalized Income after Taxes	$0.81M
EBIT	$2.02M
EBITDA	$3.29M
Weighted-Average Shares Outstanding (Basic)	30.30M
Weighted-Average Shares Outstanding (Diluted)	31.17M
Earnings per Share (EPS) (Basic)	$0.03
Earnings per Share (EPS) (Diluted)	$0.03
Balance Sheet Financials
Current Assets	$18.76M
Property, Plant, and Equipment	$1.72M
Long-Term Assets	$6.14M
Total Assets	$24.90M
Current Liabilities	$4.25M
Long-Term Debt	$0.12M
Long-Term Liabilities	$0.34M
Total Liabilities	$4.58M
Common Equity	$20.32M
Tangible Shareholders Equity	$20.32M
Shareholders Equity	$20.32M
Common Shares Outstanding	31.06M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$2.06M
Cash Flow from Investing Activities	$-0.20M
Cash Flow from Financial Activities	$0.08M
Beginning Cash	$1.68M
End Cash	$3.62M
Increase/Decrease in Cash	$1.94M
Stock-Based Compensation	$0.18M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.42
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.01
Debt to Equity Ratio	0.01
Gross Margin	10.23%
Operating Margin	3.72%
EBIT Margin	3.72%
EBITDA Margin	6.05%
Pre-Tax Profit Margin	3.79%
Profit Margin	1.49%
Free Cash Flow	$1.87M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	2.18
Inventory Turnover	5.21
Receiveable Turnover	10.01
Days Sales in Receivables	36.46
Return on Equity	3.98%
Return on Tangible Equity	3.98%
Return on Assets	3.24%
Return on Investments	3.95%
Book Value Per Share	$0.65
Free Cash Flow per Share	$0.06
Operating Cash Flow per Share	$0.07

Data from Zacks Investment Research, Inc.